Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
114.64
+0.70 (0.61%)
Dec 20, 2024, 4:00 PM EST - Market closed
Ligand Pharmaceuticals Employees
Ligand Pharmaceuticals had 58 employees as of December 31, 2023. The number of employees decreased by 18 or -23.68% compared to the previous year.
Employees
58
Change (1Y)
-18
Growth (1Y)
-23.68%
Revenue / Employee
$2,627,966
Profits / Employee
$780,069
Market Cap
2.17B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Ardent Health Partners | 23,000 |
CONMED | 4,000 |
Azenta | 3,300 |
Premier | 2,900 |
NeoGenomics | 2,100 |
GeneDx Holdings | 1,000 |
Iovance Biotherapeutics | 557 |
Geron | 141 |
LGND News
- 12 days ago - Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance - Business Wire
- 4 weeks ago - Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies - Seeking Alpha
- 5 weeks ago - Ligand to Present at Stifel 2024 Healthcare Conference - Business Wire
- 6 weeks ago - Ligand Pharmaceuticals Incorporated (LGND) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance - Business Wire
- 7 weeks ago - Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston - Business Wire
- 2 months ago - Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024 - Business Wire
- 3 months ago - Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy - Business Wire